Nyxoah Appoints New CCO for U.S. Market Push

Nyxoah (NYXH) has released an update.

Nyxoah SA, a medical technology firm specializing in Obstructive Sleep Apnea treatments, has appointed Scott Holstine as Chief Commercial Officer to spearhead the U.S. launch of their Genio system. Holstine’s extensive experience in medical device industry commercialization and team building is expected to drive the company’s market strategy and execution. The company is preparing for FDA approval and U.S. commercialization, buoyed by positive clinical study results and international success.

For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.